Blood-Based Extracellular Vesicle Diagnostic Architecture for Early Detection, Disease Monitoring, Therapeutic Guidance, and Precision Medicine
Program Code: HEMOREGEN-DX-002
Division: HEMOREGEN-DX
Parent Program: HEMOREGEN-721
Classification: Liquid Biopsy and Precision Diagnostics Platform
Status: Master Diagnostic Platform v1.0
EXECUTIVE SUMMARY
The EV Liquid Biopsy Platform establishes a comprehensive blood-based diagnostic ecosystem utilizing extracellular vesicles as dynamic molecular reporters of physiological and pathological states.
Within PROJECT HEMOREGEN-721, EV liquid biopsy is defined as a non-invasive systems biology diagnostic capable of continuously interrogating:
- Organ health
- Immune status
- Tumor evolution
- Regenerative capacity
- Metabolic adaptation
- Therapeutic response
- Disease progression
Unlike conventional tissue biopsy, EV liquid biopsy provides a real-time, whole-body communication snapshot.
SECTION I — PLATFORM ARCHITECTURE
Core Diagnostic Principle
Every organ continuously releases extracellular vesicles into circulation.
These vesicles contain:
- Molecular fingerprints
- Functional state information
- Disease-associated signatures
- Therapeutic response indicators
Diagnostic Workflow
Stage 1
Blood Collection
Input:
- Peripheral blood
Output:
- Plasma fraction
Stage 2
EV Isolation
Methods:
Method | Purpose |
Ultracentrifugation | Research-grade isolation |
Size Exclusion Chromatography | High-fidelity purification |
Immunocapture | Targeted enrichment |
Microfluidics | Clinical deployment |
Stage 3
Multi-Omic Analysis
Outputs:
- RNA profiles
- Protein profiles
- Lipid profiles
- Surface-marker profiles
Stage 4
Computational Classification
Outputs:
- Disease probability
- Organ involvement
- Progression risk
- Therapeutic response
SECTION II — EV LIQUID BIOPSY INFORMATION LAYERS
Layer A
Identity Layer
Purpose:
Determine EV origin.
Examples:
Source | Biomarkers |
Liver | miR-122 |
Brain | miR-124 |
Endothelium | CD31 |
T Cell | CD3 |
Tumor | EpCAM-associated markers |
Layer B
Functional Layer
Purpose:
Determine biological activity.
Examples:
- Inflammation
- Regeneration
- Immune activation
- Tolerance
Layer C
Disease Layer
Purpose:
Detect pathology.
Examples:
- Cancer
- Autoimmunity
- Infection
- Fibrosis
Layer D
Response Layer
Purpose:
Monitor therapy effectiveness.
Examples:
- Tumor regression
- Immune restoration
- Regenerative response
SECTION III — ONCOLOGY LIQUID BIOPSY SYSTEM
Cancer Detection Module
Primary EV Biomarkers
- Tumor-associated proteins
- Oncogenic miRNAs
- Checkpoint cargo
- Metastatic signaling markers
Diagnostic Outputs
Parameter | Purpose |
Tumor Presence Score | Detection |
Tumor Burden Index | Disease load |
Metastatic Potential Index | Dissemination risk |
Immune Escape Index | Immunotherapy planning |
Minimal Residual Disease Module
Purpose:
Detect microscopic residual disease following treatment.
Applications:
- Surgical monitoring
- Post-radiotherapy assessment
- Post-chemotherapy surveillance
Recurrence Forecasting Module
Purpose:
Identify recurrence before clinical manifestation.
SECTION IV — IMMUNE LIQUID BIOPSY SYSTEM
APC Priming Monitor
Derived From:
HEMOREGEN-IMM-001
Biomarkers:
- MHC complexes
- CD80
- CD86
- IL-12
Purpose:
Immune competence assessment.
Tolerance Monitor
Derived From:
HEMOREGEN-IMM-002
Biomarkers:
- FOXP3-associated cargo
- IL-10
- TGFβ
Purpose:
Tolerance assessment.
Cytotoxicity Monitor
Derived From:
HEMOREGEN-IMM-003
Biomarkers:
- Granzyme B
- TRAIL
- IFN-γ
Purpose:
Immune surveillance assessment.
Exhaustion Monitor
Derived From:
HEMOREGEN-IMM-005
Biomarkers:
- PD-L1
- TOX-associated transcripts
- TIM-3-associated cargo
Purpose:
Immune dysfunction assessment.
SECTION V — ORGAN HEALTH LIQUID BIOPSY SYSTEM
Brain Monitoring Module
Biomarkers:
- Neural miRNAs
- Neuroinflammatory cargo
- Synaptic regulatory proteins
Applications:
- Neurodegeneration
- Neuroinflammation
Liver Monitoring Module
Biomarkers:
- miR-122
- Hepatic proteins
Applications:
- Liver injury
- Fibrosis
- Metabolic disease
Cardiac Monitoring Module
Biomarkers:
- Cardiac proteins
- Stress-response cargo
Applications:
- Heart failure
- Ischemic injury
Kidney Monitoring Module
Biomarkers:
- Nephron-derived EV markers
Applications:
- Renal dysfunction
- Fibrosis
SECTION VI — REGENERATIVE MONITORING SYSTEM
Injury Detection Module
Detects:
- Tissue damage
- Early repair signaling
Regeneration Tracking Module
Biomarkers:
- Growth factors
- Regenerative miRNAs
- Stem-cell communication cargo
Fibrosis Risk Module
Biomarkers:
- TGFβ
- ECM remodeling proteins
SECTION VII — EV DIAGNOSTIC ALGORITHM ARCHITECTURE
Algorithm Layer 1
Source Attribution
Determines:
Origin tissue.
Algorithm Layer 2
State Classification
Determines:
Physiological vs pathological state.
Algorithm Layer 3
Risk Stratification
Determines:
Disease probability.
Algorithm Layer 4
Longitudinal Modeling
Determines:
Progression trajectory.
Algorithm Layer 5
Therapeutic Prediction
Determines:
Response likelihood.
SECTION VIII — HEMOREGEN LIQUID BIOPSY INDICES
Disease Detection Index (DDI)
Range:
0–100
Measures:
Disease probability.
Organ Integrity Index (OII)
Range:
0–100
Measures:
Organ health.
Immune Competence Index (ICI)
Range:
0–100
Measures:
Immune functionality.
Regenerative Capacity Index (RCI)
Range:
0–100
Measures:
Repair potential.
Therapeutic Response Index (TRI)
Range:
0–100
Measures:
Expected treatment benefit.
SECTION IX — COMPANION DIAGNOSTIC ARCHITECTURE
CDX-ONC
Oncology Companion Diagnostics
Applications:
- Treatment selection
- Response monitoring
CDX-IMM
Immune Companion Diagnostics
Applications:
- Immunotherapy optimization
CDX-REGEN
Regenerative Companion Diagnostics
Applications:
- Tissue engineering
- Cell therapy monitoring
CDX-DTWIN
Digital Twin Companion Diagnostics
Applications:
- Predictive systems medicine
SECTION X — HEMOREGEN THERAPEUTIC ENGINEERING BLUEPRINT
HEM-DX-RX-006
Universal EV Liquid Biopsy Platform
Applications:
- Multi-disease diagnostics
HEM-DX-RX-007
Cancer Surveillance Platform
Applications:
- Oncology
- MRD monitoring
HEM-DX-RX-008
Immune Monitoring Platform
Applications:
- Immunotherapy
- Autoimmunity
HEM-DX-RX-009
Organ Health Surveillance Platform
Applications:
- Precision medicine
HEM-DX-RX-010
Digital Twin Diagnostic Platform
Applications:
- Predictive healthcare
- Systems biology
SECTION XI — PROJECT RHENOVA INTEGRATION
The EV Liquid Biopsy Platform provides the diagnostic input layer for:
- Human Organ Communication Connectome
- Whole-Body EV Simulation Engine
- Digital Twin Architecture
- EV Therapeutic Engineering Programs
- Multi-Omic Disease Modeling
TRANSLATIONAL DEVELOPMENT ROADMAP
H1 — Biomarker Discovery
- Multi-omic EV profiling
- Source attribution systems
H2 — Analytical Validation
- Isolation standardization
- Assay development
H3 — Clinical Validation
- Longitudinal cohorts
- Multi-disease studies
H4 — Companion Diagnostic Development
- Regulatory validation
- Clinical utility assessment
H5 — Clinical Deployment
- Precision diagnostics
- Population-scale monitoring
NEXT DELIVERABLE
HEMOREGEN-DX-003 — EV Communication Failure Atlas
Will establish:
- Communication failure taxonomy
- Disease-specific network collapse signatures
- EV communication drift architecture
- Organ communication failure maps
- Early-warning biomarkers
- Communication restoration targeting framework
MASTER REGISTRY INDEX
HEMOREGEN-DX-002 — EV Liquid Biopsy Platform
HEM-DX-RX-006 — Universal EV Liquid Biopsy Platform
HEM-DX-RX-007 — Cancer Surveillance Platform
HEM-DX-RX-008 — Immune Monitoring Platform
HEM-DX-RX-009 — Organ Health Surveillance Platform
HEM-DX-RX-010 — Digital Twin Diagnostic Platform
HEMOREGEN-721-PROG-0001 — Project HEMOREGEN-721 Master Program
SCF-EV-LBX-0001 — EV Liquid Biopsy Systems Atlas
SCF-EV-MRD-0001 — Minimal Residual Disease Monitoring Framework
SCF-EV-CDX-0002 — Precision Liquid Biopsy Companion Diagnostic Architecture